KNSA.NASDAQ
- Kiniksa Pharmaceuticals International plc
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-0.15/--
|
Enterprise Value
1.65B
|
Balance Sheet |
Book Value Per Share
6.11
|
Cash Flow |
Cash Flow Yield
0.02
|
Income Statement |
Total Revenue
270.26M
|
Operating Revenue Per Share
3.49
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/10/31 19:01 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |